Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other Non-Current Liabilities (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Other Non-Current Liabilities for 16 consecutive years, with $701000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 9.2% to $701000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $701000.0, a 9.2% decrease, with the full-year FY2025 number at $701000.0, down 9.2% from a year prior.
  • Other Non-Current Liabilities was $701000.0 for Q4 2025 at Anika Therapeutics, down from $761000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $1.7 million in Q2 2021 to a low of $398000.0 in Q4 2022.
  • A 5-year average of $718368.4 and a median of $684000.0 in 2022 define the central range for Other Non-Current Liabilities.
  • Biggest YoY gain for Other Non-Current Liabilities was 102.85% in 2021; the steepest drop was 96.07% in 2021.
  • Anika Therapeutics' Other Non-Current Liabilities stood at $1.3 million in 2021, then crashed by 68.36% to $398000.0 in 2022, then increased by 1.51% to $404000.0 in 2023, then surged by 91.09% to $772000.0 in 2024, then fell by 9.2% to $701000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Other Non-Current Liabilities are $701000.0 (Q4 2025), $761000.0 (Q3 2025), and $756000.0 (Q2 2025).